and providing information; to train personnel and to be able to respond to a collection of information; to search data sources; to complete and review the collection of information; and to transmit or otherwise disclose the information. The total annual burden hours estimated for this ICR are summarized in the table below.

### TOTAL ESTIMATED ANNUALIZED BURDEN—HOURS

<table>
<thead>
<tr>
<th>Type of information collection</th>
<th>Number of respondents</th>
<th>Number of responses per respondent</th>
<th>Total responses</th>
<th>Average burden per response (in hours)</th>
<th>Total burden hours</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mail/email 1</td>
<td>1,670</td>
<td>1</td>
<td>1,670</td>
<td>0.26</td>
<td>434.2</td>
</tr>
<tr>
<td>Telephone</td>
<td>1,670</td>
<td>1</td>
<td>1,670</td>
<td>0.26</td>
<td>434.2</td>
</tr>
<tr>
<td>Web-based</td>
<td>1,666</td>
<td>1</td>
<td>1,666</td>
<td>0.25</td>
<td>416.5</td>
</tr>
<tr>
<td>Focus Groups</td>
<td>1,666</td>
<td>1</td>
<td>1,666</td>
<td>1.0</td>
<td>1,666</td>
</tr>
<tr>
<td>In-person</td>
<td>1,666</td>
<td>1</td>
<td>1,666</td>
<td>1.0</td>
<td>1,666</td>
</tr>
<tr>
<td>Automated 2</td>
<td>1,666</td>
<td>1</td>
<td>1,666</td>
<td>1.0</td>
<td>1,666</td>
</tr>
<tr>
<td>Cognitive Testing</td>
<td>5,000</td>
<td>1</td>
<td>5,000</td>
<td>1.41</td>
<td>7,050</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>15,004</strong></td>
<td><strong>15,004</strong></td>
<td><strong>13,333</strong></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

1 May include telephone non-response follow-up, in which case the burden will not change.

2 May include testing of database software, CAPI software, or other automated technologies.

---

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**National Institutes of Health**

**National Institute of Dental & Craniofacial Research; Notice of Meeting**

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of a meeting of the National Advisory Dental and Craniofacial Research Council.

The meeting will be open to the public as indicated below, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Advisory Dental and Craniofacial Research Council.

**AGENDA:**

- Report to the Director, NIDCR.
- Place: National Institutes of Health, Building 31C, Conference Room 10, 31 Center Drive, Bethesda, MD 20892.
- Closed: 2:00 p.m. to 3:00 p.m.
- Agenda: To review and evaluate grant applications.
- Place: National Institutes of Health, Building 31C, Conference Room 10, 31 Center Drive, Bethesda, MD 20892.

**Contact Person:** Alicia J. Dombroski, Ph.D., Director, Division of Extramural Activities, Natl Inst of Dental and Craniofacial Research, National Institutes of Health, Bethesda, MD 20892, 301–594–4805, adombroski@nidcr.nih.gov

In the interest of security, NIH has instituted stringent procedures for entrance onto the NIH campus. All visitor vehicles, including taxicabs, hotel, and airport shuttles will be inspected before being allowed on campus. Visitors will be asked to show one form of identification (for example, a government-issued photo ID, driver’s license, or passport) and to state the purpose of their visit.

Information is also available on the Institute’s/Center’s home page: http://www.nidcr.nih.gov/about, where an agenda and any additional information for the meeting will be posted when available. (Catalogue of Federal Domestic Assistance Program Nos. 93.121, Oral Diseases and Disorders Research, National Institutes of Health, HHS)


Natasha M. Copeland
Program Analyst, Office of Federal Advisory Committee Policy.

**FOR FURTHER INFORMATION CONTACT:**

Dr. Warren Casey, Director, National Institute of Dental & Craniofacial Research; Division of the Executive Secretariat.

[FR Doc. 2017–08296 Filed 4–24–17; 8:45 am]

**BILLING CODE 4165–15–P**

---

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**National Institutes of Health**

**Interagency Coordinating Committee on the Validation of Alternative Methods; Notice of Public Meeting; Request for Public Input**

**SUMMARY:** The Interagency Coordinating Committee on the Validation of Alternative Methods (ICCVAM) will hold a public forum to share information and facilitate direct communication of ideas and suggestions from stakeholders. Interested persons may attend in person or view the meeting remotely by webcast. Time will be set aside for questions and public statements on the topics discussed.

Registration is requested for both public attendance and oral statements, and required for remote access. Information about the meeting and registration are available at [http://ntp.niehs.nih.gov/go/iccvamforum-2017](http://ntp.niehs.nih.gov/go/iccvamforum-2017).

**DATES:**

- **Meeting:** May 23, 2017, 9:00 a.m. to approximately 4:00 p.m. Eastern Daylight Time (EDT).
- **Registration for Onsite Meeting:** Deadline is May 12, 2017.
- **Registration for Webcast:** Deadline is May 23, 2017.
- **Submission of Oral Public Statements:** Deadline is May 12, 2017.

**ADDRESSES:**

- **Meeting Location:** William H. Natcher Conference Center, National Institutes of Health, Bethesda, MD 20892.

**FOR FURTHER INFORMATION CONTACT:**

Dr. Warren Casey, Director, National
Toxicology Program Interagency Center for the Evaluation of Alternative Toxicological Methods (NICEATM); email: warren.casey@nih.gov; telephone: (919) 316–4729.

SUPPLEMENTARY INFORMATION:

Background: ICCVAM, a congressionally mandated committee, promotes the development and validation of alternative testing strategies that protect human health and the environment while replacing, reducing, or refining animal use.

ICCVAM’s goals include promotion of national and international partnerships between governmental and nongovernmental groups, including academia, industry, advocacy groups, and other key stakeholders. To foster these partnerships ICCVAM initiated annual public forums in 2014 to share information and facilitate direct communication of ideas and suggestions from stakeholders (79 FR 25136).

This year’s meeting will be held on May 23, 2017, at the National Institutes of Health (NIH) in Bethesda, MD. The meeting will include presentations by NICEATM and ICCVAM members on current activities related to the development and validation of alternative test methods and approaches, including discussions of the proposed strategic roadmap to establish new approaches for evaluating the safety of chemicals and medical products in the United States. These new approaches are anticipated to increase confidence in alternative methods and improve their relevance to human health outcomes while maximizing efficiency and maintaining a commitment to replace, reduce, and refine animal use.

Following each presentation, there will be an opportunity for participants to ask questions of the ICCVAM members. Instructions for submitting questions will be provided to remote participants prior to the webcast. The agenda will also include time for participants to make public oral statements relevant to the ICCVAM mission and current activities.

Preliminary Agenda and Other Meeting Information: The preliminary agenda, list of discussion topics, background materials, ICCVAM roster, and public statements submitted prior to the meeting will be posted by May 16 at http://ntp.niehs.nih.gov/go/iccvmforum-2017. Interested individuals are encouraged to visit this Web page to stay abreast of the most current meeting information.

Registration: This meeting is open to the public with time scheduled for questions and oral public statements following presentations from ICCVAM and NICEATM. The public may attend the meeting at NIH, where attendance is limited only by the space available, or view remotely by webcast. Those planning to attend the meeting in person are encouraged to register at http://ntp.niehs.nih.gov/go/iccvmforum-2017 by May 12, 2017, to facilitate planning for appropriate meeting space. Those planning to view the webcast must register at http://ntp.niehs.nih.gov/go/iccvmforum-2017; registration will be available through May 23, 2017. The URL for the webcast will be provided in the email confirming registration.

Visitor and security information for visitors to NIH is available at http://www.nih.gov/about/visitor/index.htm. Individuals with disabilities who need accommodation to participate in this event should contact Dr. Elizabeth Maull at phone: (919) 316–4668 or email: maull@niehs.nih.gov. TTY users should contact the Federal TTY Relay Service at 800–877–8339. Requests should be made at least five business days in advance of the event.

Request for Oral Public Statements:

Each presentation will be followed by an opportunity for participants to ask questions of the presenter. Attendees need not register in advance for the opportunity to ask questions or make comments specific to presentations. Instructions for submitting questions or comments will be provided to remote participants prior to the webcast. In addition to time for questions or comments following each scheduled presentation, time will be allotted during the meeting for oral public statements with associated slides on topics relevant to ICCVAM’s mission and topics under discussion including the U.S. strategic roadmap. The number and length of presentations may be limited based on available time. Submitters will be identified by their name and affiliation and/or sponsoring organization, if applicable. Persons submitting public statements and/or associated slides should include their name, affiliation (if any), mailing address, telephone, email, and sponsoring organization (if any) with the document. National Toxicology Program guidelines for public statements are at http://ntp.niehs.nih.gov/ntp/about_ntp/guidelines_public_comments_508.pdf.

Persons wishing to present oral public statements should email ICCVAMquestions@niehs.nih.gov by May 12, 2017, to request permission to present oral public statements by teleconference line. Persons who are unable to attend the meeting in person or wish to present oral public statements should email ICCVAMquestions@niehs.nih.gov by May 12, 2017 to arrange to present statements via teleconference line.

Responses to this notice are voluntary. No proprietary, classified, confidential, or sensitive information should be included in statements submitted in response to this notice or presented during the meeting. This request for input is for planning purposes only and is not a solicitation for applications or an obligation on the part of the U.S. Government to provide support for any ideas identified in response to the request. Please note that the U.S. Government will not pay for the preparation of any information submitted or for its use of that information.

Background Information on ICCVAM and NICEATM: ICCVAM is an interagency committee composed of representatives from 16 federal regulatory and research agencies that require, use, generate, or disseminate toxicological and safety testing information. ICCVAM conducts technical evaluations of new, revised, and alternative safety testing methods and integrated testing strategies with regulatory applicability. ICCVAM also promotes the scientific validation and regulatory acceptance of testing methods that more accurately assess the safety and hazards of chemicals and products and replace, reduce, or refine animal use.

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

SUMMARY: The inventions listed below are owned by an agency of the U.S. Government and are available for licensing to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.

FOR FURTHER INFORMATION CONTACT: Chris Kornak, 240–627–3705, chris.kornak@nih.gov. Licensing information and copies of the U.S. patent applications listed below may be obtained by communicating with the indicated licensing contact at the Technology Transfer and Intellectual Property Office, National Institute of Aging and Infectious Diseases, 5601 Fishers Lane, Rockville, MD 20852; tel. 301–496–2644. A signed Confidential Disclosure Agreement will be required to receive copies of unpublished patent applications.

SUPPLEMENTARY INFORMATION: Technology description follows.

A Second CD4-Binding Region of HIV–1 gp120 Critical for Viral Infectivity: New Methods for Treatment and Vaccine Development

Description of Technology: It is believed that immunization with an effective immunogen based on the HIV–1 envelope glycoprotein can elicit a neutralizing antibody response, which may be protective against HIV–1 infection. NIAID researchers have discovered a new critical component of the CD4-binding site in gp120, named CD4–BS2, which is exclusively formed in the trimeric envelope conformation. It was further found that this newly recognized region is critical for the progression of the fusogenic mechanism that leads to HIV–1 entry and infection of the cells. This discovery may lead to new methods of treatment, for treating HIV–1, as well as to the production of new vaccine immunogens.

This technology is available for licensing for commercial development in accordance with 35 U.S.C. 209 and 37 CFR part 404, as well as for further development and evaluation under a research collaboration.

Potential Commercial Applications: New target for HIV therapeutics and vaccine development.

Competitive Advantages: A new molecular target discovered in this invention may facilitate the development of next-generation HIV therapeutics and vaccines.

Development Stage: Proof-of-concept studies demonstrate that CD4 binding to CD4–BS2 is critical for triggering gp120 conformational changes that enable coreceptor binding and HIV–1 infectivity. Animal studies are ongoing.

Inventors: Paolo Lusso, NIAID, NIH; and Qingbo Liu, NIAID, NIH.


Licensing Contact: Chris Kornak, 240–627–3705, chris.kornak@nih.gov.

Collaborative Research Opportunity: The Technology Transfer and Intellectual Property Office (TTIPO) is seeking parties interested in collaborative research to further co-develop HIV–1 vaccines and/or inhibitors that target the newly recognized region. For collaboration opportunities, please contact Chris Kornak, 240–627–3705, chris.kornak@nih.gov.


Suzanne Frisbie,
Deputy Director, Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases.

[FR Doc. 2017–08351 Filed 4–24–17; 8:45 am]
BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute on Aging; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial